MIDDLE EAST & NORTH AFRICA
We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2018 financial year.
United Arab Emirates
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The MENA pharmaceutical sector was valued at USD26,0 billion as at 30 June 2018.
- The top nine major markets (which include, inter alia, the Kingdom of Saudi Arabia, Algeria, Egypt and the United Arab Emirates) were value at USD17,4 billion and grew 9,3%.
Source: June 2018 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2018||2017 (CER)||% change|
|High Potency & Cytotoxics||193||242||(20)|